XERS Stock Recent News

Xeris Biopharma reports notable revenue growth in Q2 2023 for its main products, Gvoke, Keveyis, and Recorlev. The company's expenses have also increased, with a rise in the cost of goods sold and research and development expenses. Xeris has a satisfactory reserve for short-term needs but carries significant long-term debt, which may deter some investors.

Xeris Biopharma has reported another quarter of record revenue driven by continued strong demand for the biopharmaceutical company's products Gvoke, Keveyis, and Recorlev. For the quarter which ended on June 30, 2023, the company achieved sales of $38 million, up 50% year-over-year and 14% sequentially.

Xeris Biopharma said it has shipped more than 1 million units of Gvoke, its ready-to-use liquid glucagon for the treatment of severe hypoglycemia in adults and children aged two years and older with diabetes. “We are proud to celebrate this major milestone of having shipped over 1 million units of Gvoke since its launch,” Xeris CEO Paul R.

Xeris Biopharma Holdings (NASDAQ:XERS) told investors that the first participant has been dosed in a multi-center, open-label, Phase 2 study of XP-8121 (levothyroxine sodium) for the treatment of adults with hypothyroidism. The biopharmaceutical company explained that the Phase 2 study (NCT05823012) is a non-randomized, open-label, single-arm, self-controlled study of XP-8121.

Xeris Biopharma Holdings Inc is a growing healthcare company with strong revenue growth and a solid balance sheet, making it an attractive investment option. XERS has a range of successful products, such as Glucagon and Gvoke, and is aggressively securing patents to stay ahead of competition. XERS is expected to achieve profitability soon, with a breakeven cash flow by Q4 2023, and an estimated EPS of $0.23 by 2026.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q1 2023 Earnings Conference Call May 9, 2023 8:30 AM ET Company Participants Allison Wey - Senior Vice President, Investor Relations, and Corporate Communications Paul Edick - Chairman and Chief Executive Officer Steve Pieper - Chief Financial Officer Conference Call Participants Oren Livnat - H.C. Wainwright Glen Santangelo - Jefferies Roanna Ruiz - SVB Securities Operator Hello all and warm welcome to the Xeris Biopharma Holding First Quarter 2023 Financial Results Call.

Xeris Biopharma Holdings (NASDAQ:XERS) has started 2023 strongly, achieving record revenue during the first quarter.   For the quarter ended March 31, 2023, revenue rose 50.4% to $33.2 million from $22 million in the first quarter of 2022.

Xeris Biopharma Holdings (NASDAQ:XERS) said it has received a US patent covering formulations in its Gvoke product line used to treat severe hypoglycemia.  The patent issued by the US Patent and Trademark Office covers methods for using the formulations in treating hypoglycemia as well as manufacturing methods, the biopharma company said.

Xeris Biopharma Holdings (NASDAQ:XERS) told investors it has entered into a platform research evaluation collaboration and option agreement with Regeneron Pharmaceuticals Inc. Under the terms of the agreement, the company said it will use its proprietary drug-formulation platform, XeriJect, to develop ultra-highly concentrated, ready-to-use, small-volume subcutaneous injections of two undisclosed monoclonal antibodies (mAbs) developed by Regeneron.  Xeris will receive an upfront payment and potential milestone payments for preclinical achievements.

Xeris Biopharma Holdings (NASDAQ:XERS) Inc has announced the appointment of Ricki Fairley to its board of directors on March 27, 2023, increasing the size of the company's board to nine members. The growth-oriented biopharmaceutical firm said Fairley has over 35 years of marketing experience including 20 years in brand management at Johnson & Johnson (NYSE:JNJ), Nabisco, Reckitt & Colman, and The Coca-Cola Company (NYSE:KO).